Literature DB >> 7791073

Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats.

A Gobert1, F Lejeune, J M Rivet, V Audinot, A Newman-Tancredi, M J Millan.   

Abstract

In this study, we used a complementary in vivo electrophysiological and (in individual rats) neurochemical approach to characterize the actions of chemically diverse serotonin (5-HT)1A receptor ligands at central 5-HT1A autoreceptors as compared to dopamine (DA) D2 autoreceptors and presynaptic alpha-2 adrenergic receptors (ARs). The novel, high efficacy, 5-HT1A agonists, WY 48,723 (an arylpiperazine), (+)-flesinoxan (a benzodioxane) and S 14671 and S 14506 (methoxynaphtylpiperazines) mimicked the aminotetralin, 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), in inhibiting the firing of dorsal raphe nucleus (DRN) neurons. Similarly, the firing rate of DRN neurons was reduced by the "partial" agonists, MDL 73005EF, BMY 7378, NAN-190, tandospirone and the novel pyrimidinylpiperazine, zalospirone. Furthermore, S 14489, S 15535 and S 15931, novel benzodioxopiperazines, which behave as antagonists at postsynaptic 5-HT1A receptors, inhibited completely DRN firing, whereas the methoxyphenylpiperazine, WAY 100,135, and the aryloxoarylamine, (-)-tertatolol, were ineffective. Indeed, in analogy to spiperone, both WAY 100,135 and (-)-tertatolol behaved as apparently competitive antagonists in that, in their presence, the dose-response curves for inhibition of DRN firing by S 14671, S 14506 or 8-OH-DPAT were shifted in parallel to the right with no loss of maximal effect. In distinction to WAY 100,135 and (-)-tertatolol, a further novel, putative "antagonist," SDZ 216-525 (a benzoisothiazolpiperazine) weakly inhibited the electrical activity of the DRN. With the exception of (-)-tertatolol, which behaved as a weak agonist, a very similar pattern of inhibition of 5-HT turnover was seen in the striatum (innervated by the DRN), the hippocampus and the hypothalamus (DRN and median raphe nucleus) and the spinal cord (nucleus raphe magnus), with the striatum displaying the greatest sensitivity. Drug potency for inhibition of firing and turnover was highly correlated (r = 0.80-0.82) and these actions were significantly correlated to affinity at (hippocampal) 5-HT1A receptors (r = 0.62-0.73). As concerns DA D2 autoreceptors, the agonist action of apomorphine in reducing DA turnover were mimicked only by 8-OH-DPAT, whereas the majority of the other 5-HT1A ligands, in analogy to raclopride, enhanced DA turnover. The facilitation of DA turnover appeared to reflect direct blockade of DA D2 autoreceptors because potency was correlated powerfully to affinity at these D2 sites (r = 0.89).(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791073

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Intra-median raphe nucleus (MRN) infusions of muscimol, a GABA-A receptor agonist, reinstate alcohol seeking in rats: role of impulsivity and reward.

Authors:  Anh Dzung Lê; Anh Lê Dzung; Douglas Funk; Stephen Harding; Walter Juzytsch; Zhaoxia Li; Paul J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2007-09-22       Impact factor: 4.530

Review 2.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study.

Authors:  S E Gartside; E M Clifford; P J Cowen; T Sharp
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats.

Authors:  Zeyad Schwen; Yosuke Matsuta; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  Am J Physiol Renal Physiol       Date:  2013-10-23

5.  Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex.

Authors:  M Sakaue; P Somboonthum; B Nishihara; Y Koyama; H Hashimoto; A Baba; T Matsuda
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

6.  Exploring the role of 5-HT1A receptors in the regulation of prepulse inhibition in mice: implications for cross-species comparisons.

Authors:  Maarten van den Buuse
Journal:  ACS Chem Neurosci       Date:  2012-12-18       Impact factor: 4.418

Review 7.  Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

Authors:  Pau Celada; Analía Bortolozzi; Francesc Artigas
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

8.  Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  C Marin; E Aguilar; M C Rodríguez-Oroz; G D Bartoszyk; J A Obeso
Journal:  Psychopharmacology (Berl)       Date:  2009-01-22       Impact factor: 4.530

9.  Effects of duloxetine and WAY100635 on pudendal inhibition of bladder overactivity in cats.

Authors:  Jeremy Reese; Zhiying Xiao; Zeyad Schwen; Yosuke Matsuta; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  J Pharmacol Exp Ther       Date:  2014-03-25       Impact factor: 4.030

10.  Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats.

Authors:  Esther Berrocoso; M Dolores De Benito; Juan A Mico
Journal:  Psychopharmacology (Berl)       Date:  2007-03-29       Impact factor: 4.415

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.